CClinicalTrials.gg
TerminatedNCT02110381Updated Mar 28, 2017Results posted

Assessing Alternative Approaches for Blood Pressure Control: A3BC Trial

An interventional study of Device guided breathing RESPeRATE and Isometric hand grip Zona Plus in Hypertension, sponsored by University of Michigan. Terminated at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2017-03-28.

Sponsored by University of Michigan · Not applicable, Interventional, and Treatment

Why this study was terminated
It was a pilot study and we enrolled sufficient numbers to evaluate the proposed outcomes.
Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

An estimated 76 million adults in the United States over the age of 20 have hypertension (HTN); which translates into 1 out of 3 adults. Globally the prevalence of HTN is over 25% for adults, and accounts for approximately 13.5% of all deaths. Given the aging of the population together with increases in obesity and sedentary behavior, it is not surprising that HTN is projected to increase significantly over the next several decades; with over 1.5 billion adults having HTN by the year 2025. Thus the public health implications to preventing and/or reducing elevations in blood pressure are substantial.

This study compares the efficacy of two different non-pharmacologic interventions (device guided breathing and isometric hand grip exercises) used alone and in combination for lowering blood pressure. This pilot study will include 30 adults with stage 1 hypertension. The primary outcome is the change in blood pressure from baseline to 8 weeks. Secondary outcomes include change in blood pressure from 8 weeks to 16 weeks and acceptability of the interventions by participants. The knowledge gained from this study can provide information on non-pharmacologic methods that may be useful in decreasing blood pressure. Such knowledge may be especially useful for patients for whom access to medications and health care is limited and among patients unwilling to take or intolerant to pharmacologic therapies.

02

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • High blood pressure
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's enrollment of 32 is below the median of 90 across 4,995 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

University of Michigan is the lead sponsor of 1,475 studies on the registry; 196 are open to participants now.

Of its 162 completed or terminated interventional studies of FDA-regulated products, 128 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Are at least 21 years old, and
  • Have Stage 1 high blood pressure. (Defined as a systolic blood pressure between 140 mm Hg and 159 mm Hg (the top blood pressure number) and/or a diastolic blood pressure between 90 mm Hg and 99 mm Hg (the bottom blood pressure number) in the prior 6 months.)

Exclusion criteria

Exclusion Criteria:

  • Take drugs to control blood pressure.
  • Have a history of left ventricular hypertrophy.
  • Have a history of cardiovascular disease such as stroke, mini-strokes, heart attack, unstable angina, bypass surgery, stents, angioplasty, abnormal heart rhythms, heart failure, or peripheral artery disease.
  • Have diabetes.
  • Have a history of poor kidney function.
  • Have an upper arm circumference greater than 17 inches.
  • Are currently participating in a formal exercise or weight loss program.
  • Plan to participate in a formal exercise or weight loss program in the next 6 months.
  • Are pregnant or plan to become pregnant in the next 6 months.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Device Guided Breathing/Combination Therapy

    Participants will first do device guided breathing for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.

    Device: Device guided breathing RESPeRATE · Device: Isometric hand grip Zona Plus

  • Active comparator
    Isometric Hand Grip/Combination Therapy

    Participants will first do isometric hand grip exercises for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.

    Device: Device guided breathing RESPeRATE · Device: Isometric hand grip Zona Plus

Interventions

  • DeviceDevice guided breathing RESPeRATE

    Participants will use a device called RESPeRATE which will measure how many breaths they take per minute. A strap wraps around the participants chest that measures breathing frequency. Headphones plug into the device to inform participants about their breathing. The device will help guide participants to breathe slowly using musical tones, with a goal of about ten breaths per minute. Participants will use the breathing device 5 days per week for about 15 minutes each day. Participants will keep a log of their exercises and return it with each visit.

  • DeviceIsometric hand grip Zona Plus

    Participants will use a device called the Zona Plus, which they will hold in their hand and squeeze. A session consists of 2 minutes of squeezing the device followed by 1 minute of rest. Participants will do a total of 4 sessions (2 sessions for each hand) for a total of about 12 minutes of exercise. Participants will do these exercises 5 days per week. Participants will keep a log of their exercise and return it with each visit.

06

What researchers measure

Primary outcomes

  1. Change in Blood Pressure

    Blood pressure was measured using an automated cuff with subject in a seated position for at least 5 minutes. Six measurements were recorded at 1-minute intervals. The mean was used in analysis.

    Time frame: 8 weeks and 16 weeks

Secondary outcomes

  1. Adherence to Single Modality Exercise (Device Guided Breathing or Isometric Hand Grip)

    Subjects recorded sessions on a log; they were expected to complete 5 days/week for 8 weeks of single modality exercise for a minimum of 40 reported sessions. Results are reported as number of subjects reporting a minimum of 40 sessions.

    Time frame: 8 weeks

  2. Adherence to Dual Modality Exercise (Device Guided Breathing + Isometric Hand Grip)

    Subjects recorded sessions on a log; they were expected to complete 5 days/week for 8 weeks of single modality exercise for a minimum of 40 reported sessions. Results are reported as number of subjects reporting a minimum of 40 sessions.

    Time frame: 8 weeks

07

Results

Posted Mar 28, 2017
Limitations and caveats
small sample size

Participant flow

Medical records were screened for initial eligibility criteria between 9/2014 - 4/2015. Patients were then contacted via letter and phone to gauge interest.

Single Modality
Participant flow — Single Modality
MilestoneDevice Guided BreathingIsometric Hand Grip
Started99
Completed78
Not completed21
Dual Modality
Participant flow — Dual Modality
MilestoneDevice Guided BreathingIsometric Hand Grip
Started78
Began active treatment77
Completed57
Not completed21

Outcome measures

PrimaryChange in Blood Pressure

Blood pressure was measured using an automated cuff with subject in a seated position for at least 5 minutes. Six measurements were recorded at 1-minute intervals. The mean was used in analysis.

Time frame:
8 weeks and 16 weeks
Reported as:
Mean · mmHg (millimeters of mercury)
Change in Blood Pressure
mmHg (millimeters of mercury)Device Guided BreathingIsometric Hand Grip
Baseline Systolic Blood Pressure127.33 ± 10.15133.57 ± 17.89
Change from baseline at 8-weeks5.71 ± 13.923.43 ± 8.00
Change from baseline at 16-weeks3.50 ± 10.3446.17 ± 12.30
SecondaryAdherence to Single Modality Exercise (Device Guided Breathing or Isometric Hand Grip)

Subjects recorded sessions on a log; they were expected to complete 5 days/week for 8 weeks of single modality exercise for a minimum of 40 reported sessions. Results are reported as number of subjects reporting a minimum of 40 sessions.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Adherence to Single Modality Exercise (Device Guided Breathing or Isometric Hand Grip)
ParticipantsDevice Guided BreathingIsometric Hand Grip
Adherence to Single Modality Exercise (Device Guided Breathing or Isometric Hand Grip)74
SecondaryAdherence to Dual Modality Exercise (Device Guided Breathing + Isometric Hand Grip)

Subjects recorded sessions on a log; they were expected to complete 5 days/week for 8 weeks of single modality exercise for a minimum of 40 reported sessions. Results are reported as number of subjects reporting a minimum of 40 sessions.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Adherence to Dual Modality Exercise (Device Guided Breathing + Isometric Hand Grip)
ParticipantsDevice Guided BreathingIsometric Hand Grip
Adherence to Dual Modality Exercise (Device Guided Breathing + Isometric Hand Grip)33

Adverse events

Collected over We were in contact with subjects for 18 weeks total.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Device Guided Breathing—0/9 (0%)0/9 (0%)
Isometric Hand Grip—0/9 (0%)1/9 (11.1%)
Screen Failures—0/14 (0%)1/14 (7.1%)
Most frequent other events
Most frequent other events
EventDevice Guided BreathingIsometric Hand GripScreen Failures
Sore handsMusculoskeletal and connective tissue disorders0/91/90/14
High blood pressureCardiac disorders0/90/91/14
Tight blood pressure cuffInvestigations0/90/91/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)Device Guided BreathingIsometric Hand GripTotal
Mean56.75 ± 14.8552.67 ± 15.4854.59 ± 14.85
Sex: Female, Male
Sex: Female, Male(Participants)Device Guided BreathingIsometric Hand GripTotal
Female257
Male7411
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Device Guided BreathingIsometric Hand GripTotal
American Indian or Alaska Native101
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American011
White7714
More than one race000
Unknown or Not Reported101
Systolic Blood pressure (mmHg)
Systolic Blood pressure (mmHg)(mmHg)Device Guided BreathingIsometric Hand GripTotal
Mean127.33 ± 10.15133.57 ± 17.89129.06 ± 9.00
08

Study locations

1 site
  • University of Michigan
    Ann Arbor, Michigan 48106, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02110381
Lead sponsor
University of Michigan
Responsible party
Elizabeth A. Jackson (Associate Professor, University of Michigan) — Principal investigator
First posted
Apr 10, 2014
Start date
Sep 2014
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Mar 28, 2017
Last update
Mar 28, 2017

Study contacts

Elizabeth A Jackson, MD MPH FACC
principal investigator · University of Michigan
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion